Sign In
9 May 2011 15:41
9 May 2011
Alternative Asset Opportunities PCC Limited
(the "Company")
Interim Management Statement
This interim management statement relates to the period from 1 January 2011 to the date of publication of this statement and has been prepared solely to provide additional information in order to meet the relevant requirement of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.
The Company is a closed-ended Guernsey protected cell company with one cell known as the US Traded Life Interests Fund (the "Fund").
Investment objective
The Company's investment objective in respect of the Fund is to provide investors with an attractive capital return through investment predominantly in a diversified portfolio of U.S. Traded Life Interests ("TLIs").
Financial position and performance
Over the period to 31 March 2011, the Company's net asset value per share decreased by 2.7% to 79.3 pence. As at 31 March 2011, the shares were trading at a 31.2% discount to net asset value.
One mortality was accounted for in the period with a total face value of US$1.7 million. There have been, in aggregate, 29 policy maturities since the Fund's inception.
The Company's loan agreement with Allied Irish Banks plc was renewed in January 2011, and this provided the Company with further funding of US$6 million until 31 July 2011. As of 31 March 2011 total borrowings under the agreement amounted to US$20,592,662 and US$4,000,000 remained available to the Company.
One further mortality has been identified since 31 March 2011, but not yet formally certified, with a total face value of US$1,500,000. Apart from this, the Board is not aware of any other material events during the quarter to 31 March 2011, or in the period from 1 April 2011 to the date of this announcement, which would have had a material impact on the financial position of the Company.
Illustrative predicted yields
The table below sets out the range of illustrative predicted yields over the remaining life of the Company, with reference to the 31 March 2011 NAV of 79.3 pence per share.
31 December 2012 | 31 December 2016 | |||||||||
IRR based on exit price range5: | IRR based on exit price range5: | |||||||||
Variation in mortality1 | LE change (years) 2 | Policies surviving3 | Remaining Shares in issue 4 | 100%6 | 70%7 | Policies surviving3 | Remaining Shares in issue 4 | 100%6 | 70%7 | |
125% | -1.09 | 71.3% | 96.8% | 19.38% | 0.43% | 28.0% | 25.2% | 15.32% | 9.86% | |
110% | -0.48 | 74.2% | 100.0% | 15.67% | -4.02% | 32.1% | 35.3% | 11.86% | 6.69% | |
100% | 0.00 | 76.2% | 100.0% | 13.24% | -7.46% | 35.3% | 43.4% | 9.62% | 4.53% | |
80% | +1.20 | 80.4% | 100.0% | 8.05% | -14.94% | 42.7% | 66.7% | 5.12% | 0.18% | |
50% | +4.12 | 87.1% | 100.0% | -0.66% | -28.17% | 57.6% | 100.0% | -3.27% | -10.39% | |
30% | +8.00 | 92.0% | 100.0% | -7.27% | -38.93% | 71.1% | 100.0% | -14.39% | -42.17% | |
| Ignore Medical Underwriting8 | n/a | 83.5% | 100.0% | 6.66% | -17.97% | 45.3% | 71.8% | 5.35% | 0.37% |
Notes
1. The central case (100%) assumes that claims experience matches the valuation basis in force at 31 March 2011. The other scenarios assume that the mortality experience is higher (e.g. 110% means that if one expects 10 deaths, one instead experiences 11) or lower (e.g. 80% means that if one expects 10 deaths, one instead experiences 8).
2. This shows the effect of the mortality experience on the life expectancy (in years) for an otherwise normal 80-year-old non-smoker.
3. The proportion of policies surviving to the specified date based on the portfolio as at 31 March 2011. No allowance has been made for the policies that have matured after this date.
4. The model assumes that shares are repurchased whenever excess cash beyond that required for premium reserves is available. This column represents the number of shares still in force and not repurchased at the relevant date.
5. This shows how the return varies for a shareholder holding the shares between 31 March 2011 and the relevant date (31 December 2012 or 31 December 2016) based on the growth in the NAV per share.
6. Return based on growth in NAV per share assuming valuation at the relevant date using the valuation basis in force at 31 March 2011.
7. Return based on winding up at the relevant date assuming that the net realised proceeds of assets is 70% of the valuation calculated in accordance with the valuation basis in force at 31 March 2011.
8. Mortality outcome assuming the lives are all "normal" lives from the point of view of mortality expectations and ignoring the implied relative health from medical underwriting.
Source: SL Investment Management Limited
Top ten holdings
By reference to the most recent portfolio valuation of the Company as at 31 March 2011, the largest ten investments held by the Company, measured by life office exposure, were as follows:
Issuer | Number of policies | % of totalassets as at31 March 2011 |
American General Life Insurance Company (TX) | 13 | 17.92% |
Lincoln National Life Insurance Co | 17 | 14.31% |
Transamerica Life Insurance Company | 21 | 13.26% |
Massachusetts Mutual Life Insurance Co | 10 | 9.87% |
John Hancock Life Insurance Company | 11 | 8.48% |
Aviva Life and Annuity Company | 5 | 5.03% |
MetLife Insurance Company of Connecticut | 8 | 4.50% |
New York Life Insurance and Annuity Corp | 6 | 3.80% |
Security Life of Denver Insurance Co | 1 | 3.44% |
Pacific Life Insurance Company | 5 | 3.17% |
Company Information
Launch date 25 March 2004
EPIC TLI
Year end 30 June (from 2010 onwards)
Report & Accounts 2009 Annual Report posted December, Interim posted May
AGM November
Price Information Financial Times (under INVESTMENT COMPANIES, listed as 'AltAstsOpps.')
Investor Information
The latest available portfolio information included in the interim and annual report and accounts can be accessed via http://www.rcm.com/investmenttrusts/investors_tlif.php (under the Professional Investors section)
By order of the Board
Alternative Asset Opportunities PCC Limited
Enquiries:
Peter Ingram
Company Secretary Tel: 020 7065 1467
Follow the stocks
